National Planning Corporation’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

National Planning Corporation’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,850	Closed	-$101K	–	2078
2014 Q4	$101K	Buy	+1,850	New	+$101K	0.01%	920

Other funds holding XPH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

National Planning Corporation's XPH Position: Q1 2015 in Review

National Planning Corporation sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2015, closing a stake of 1,850 shares — an estimated $101K sold.

National Planning Corporation first reported a position in XPH in Q4 2014 and held it in 1 quarter. The position peaked at $101K in Q4 2014. 79 funds tracked by Wall St. Rank hold XPH as of Q1 2015.

National Planning Corporation reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2015 after selling out during the quarter.
National Planning Corporation sold 1,850 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2015, an estimated $101K.
National Planning Corporation first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2014 and held it in 1 quarter.
National Planning Corporation's State Street SPDR S&P Pharmaceuticals ETF position peaked at $101K in Q4 2014.
79 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.